Literature DB >> 28835492

HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.

Kaitlin Anstett1,2, Bluma Brenner2, Thibault Mesplède3,2, Mark A Wainberg1,2.   

Abstract

Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in the integrase active site that disrupt drug-protein interactions. However, resistance against the newest integrase inhibitor, dolutegravir (DTG), is associated with an R263K substitution at the C terminus of integrase that causes resistance through an unknown mechanism. The integrase C-terminal domain is involved in many processes over the course of infection and is posttranslationally modified via acetylation of three lysine residues that are important for enzyme activity, integrase multimerization, and protein-protein interactions. Here we report that regulation of the acetylation of integrase is integral to the replication of HIV in the presence of DTG and that the R263K mutation specifically disrupts this regulation, likely due to enhancement of interactions with the histone deacetylase I complex, as suggested by coimmunoprecipitation assays. Although no detectable differences in the levels of cell-free acetylation of the wild-type (WT) and mutated R263K enzymes were observed, the inhibition of cellular histone acetyltransferase enzymes sensitized the NL4.3WT virus to DTG, while NL4.3R263K was almost completely unaffected. When levels of endogenous acetylation were manipulated in virus-producing cells, inhibitors of acetylation enhanced the replication of NL4.3R263K, whereas inhibition of deacetylation greatly diminished the replication of NL4.3WT Taken together, these results point to a pivotal role of acetylation in the resistance mechanism of HIV to some second-generation integrase strand transfer inhibitors, such as DTG.IMPORTANCE This is, to our knowledge, the first report of the influence of posttranslational modifications on HIV drug resistance. Both viral replication and resistance to second-generation integrase strand transfer inhibitors of both WT and INSTI-resistant HIV strains were differentially affected by acetylation, likely as a result of altered interactions between integrase and the cellular deacetylation machinery. Many "shock and kill" strategies to eradicate HIV manipulate endogenous levels of acetylation in order to reactivate latent HIV. However, our results suggest that some drug-resistant viruses may differentially respond to such stimulation, which may complicate the attainment of this goal. Our future work will further illuminate the mechanisms involved.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antiretroviral agents; antiretroviral resistance; dolutegravir; drug resistance mechanisms; histone acetylation; human immunodeficiency virus; integrase

Mesh:

Substances:

Year:  2017        PMID: 28835492      PMCID: PMC5640858          DOI: 10.1128/JVI.00912-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor.

Authors:  Ying-Shan Han; Peter K Quashie; Thibault Mesplède; Hongtao Xu; Yudong Quan; Walter Jaeger; Thomas Szekeres; Mark A Wainberg
Journal:  J Med Virol       Date:  2015-06-09       Impact factor: 2.327

Review 2.  Evolution of HIV integrase resistance mutations.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Opin Infect Dis       Date:  2013-02       Impact factor: 4.915

3.  Strategies for production of active eukaryotic proteins in bacterial expression system.

Authors:  Orawan Khow; Sunutcha Suntrarachun
Journal:  Asian Pac J Trop Biomed       Date:  2012-02

4.  Acetylation of HIV-1 integrase by p300 regulates viral integration.

Authors:  Anna Cereseto; Lara Manganaro; Maria Ines Gutierrez; Mariaelena Terreni; Antonio Fittipaldi; Marina Lusic; Alessandro Marcello; Mauro Giacca
Journal:  EMBO J       Date:  2005-08-11       Impact factor: 11.598

5.  Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome.

Authors:  Dario Oliveira Passos; Min Li; Renbin Yang; Stephanie V Rebensburg; Rodolfo Ghirlando; Youngmin Jeon; Nikoloz Shkriabai; Mamuka Kvaratskhelia; Robert Craigie; Dmitry Lyumkis
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

6.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Authors:  Hans-Jürgen Stellbrink; Jacques Reynes; Adriano Lazzarin; Eugene Voronin; Federico Pulido; Franco Felizarta; Steve Almond; Marty St Clair; Nancy Flack; Sherene Min
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

8.  Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor.

Authors:  Peter K Quashie; Ying-Shan Han; Said Hassounah; Thibault Mesplède; Mark A Wainberg
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

9.  Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

Authors:  Antonella Castagna; Franco Maggiolo; Giovanni Penco; David Wright; Anthony Mills; Robert Grossberg; Jean-Michel Molina; Julie Chas; Jacques Durant; Santiago Moreno; Manuela Doroana; Mounir Ait-Khaled; Jenny Huang; Sherene Min; Ivy Song; Cindy Vavro; Garrett Nichols; Jane M Yeo
Journal:  J Infect Dis       Date:  2014-01-19       Impact factor: 5.226

Review 10.  Integrase and integration: biochemical activities of HIV-1 integrase.

Authors:  Olivier Delelis; Kevin Carayon; Ali Saïb; Eric Deprez; Jean-François Mouscadet
Journal:  Retrovirology       Date:  2008-12-17       Impact factor: 4.602

View more
  1 in total

Review 1.  The latest evidence for possible HIV-1 curative strategies.

Authors:  Hanh Thi Pham; Thibault Mesplède
Journal:  Drugs Context       Date:  2018-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.